Kingsoft Cloud Holdings Limited vs Novo Nordisk A/S — how do they compare? Kingsoft Cloud Holdings Limited trades at $10.06 (market cap $3.01B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 73.3× Kingsoft Cloud Holdings Limited's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.
| KC | NVO | |
|---|---|---|
Market Cap | $3.01B | $220.53B |
Sector | Technology | Health |
52-Week High | $18.21 | $71.70 |
52-Week Low | $8.58 | $35.29 |
Enterprise Value | $3.32B | $239.49B |
Dividend Yield | — | 3.63% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Trailing returns across standard periods
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →